3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Association of Depression With Past-Month Cannabis Use Among US Adults Aged 20 to 59 Years, 2005 to 2016

      research-article
      , MPH 1 , 2 , , MS 2 , , PhD 1 , 2 , 3 ,
      JAMA Network Open
      American Medical Association

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Key Points

          Question

          Did the association of depression with past-month cannabis use among US adults change from 2005 to 2016?

          Findings

          In this repeated cross-sectional study of 16 216 adults, those with depression increased their rates of cannabis use significantly faster than those without depression. In 2005 to 2006, individuals with depression had 46% higher odds of any cannabis use and 37% higher odds of near-daily cannabis use, while in 2015 to 2016, individuals with depression had 130% higher odds of any cannabis use and 216% higher odds of daily cannabis use.

          Meaning

          In this study, an increasing number of adults with depression used cannabis during the study period.

          Abstract

          This cross-sectional study examines the association of depression with past-month cannabis use among US adults and the time trends for this association from 2005 to 2016.

          Abstract

          Importance

          Despite studies showing that repeated cannabis use may worsen depressive symptoms, the popular media increasingly presents cannabis as beneficial to mental health, and many members of the public view cannabis as beneficial for depression. Therefore, cannabis use among individuals with depression may be becoming more prevalent.

          Objective

          To examine the association of depression with past-month cannabis use among US adults and the time trends for this association from 2005 to 2016.

          Design, Setting, and Participants

          This repeated cross-sectional study used data from 16 216 adults aged 20 to 59 years who were surveyed by the National Health and Nutrition Examination Survey, a national, annual, cross-sectional survey in the United States, between 2005 and 2016. Data analysis was conducted from January to February 2020.

          Exposures

          Survey year and depression, as indicated by a score of at least 10 on the Patient Health Questionnaire–9.

          Main Outcomes and Measures

          Any past-month cannabis use (ie, ≥1 use in the past 30 days) and daily or near-daily past-month cannabis use (ie, ≥20 uses in the past 30 days). Logistic regression was used to examine time trends in the prevalence of cannabis use, depression, and the association between cannabis use and depression from 2005 to 2016.

          Results

          The final analysis included 16 216 adults, of whom 7768 (weighted percentage, 48.9%) were men, 6809 (weighted percentage, 66.4%) were non-Hispanic White participants, and 9494 (weighted percentage, 65.6%) had at least some college education. They had a weighted mean age of 39.12 (95% CI, 38.23-39.40) years. Individuals with depression had 1.90 (95% CI, 1.62-2.24) times the odds of any past-month cannabis use and 2.29 (95% CI, 1.80-2.92) times the odds of daily or near-daily cannabis use compared with those without depression. The association between cannabis use and depression increased significantly from 2005 to 2016. The odds ratio for depression and any past-month cannabis use increased from 1.46 (95% CI, 1.07-1.99) in 2005 to 2006 to 2.30 (95% CI, 1.82-2.91) in 2015 to 2016. The odds ratio for depression and daily or near-daily past-month cannabis use increased from 1.37 (95% CI, 0.81-2.32) in 2005 to 2006 to 3.16 (95% CI, 2.23-4.48) in 2015 to 2016.

          Conclusions and Relevance

          The findings of this study indicate that individuals with depression are at increasing risk of cannabis use, with a particularly strong increase in daily or near-daily cannabis use. Clinicians should be aware of these trends and the evidence that cannabis does not treat depression effectively when discussing cannabis use with patients.

          Related collections

          Most cited references35

          • Record: found
          • Abstract: found
          • Article: not found

          Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013.

          Laws and attitudes toward marijuana in the United States are becoming more permissive but little is known about whether the prevalence rates of marijuana use and marijuana use disorders have changed in the 21st century.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            US Epidemiology of Cannabis Use and Associated Problems

            This review provides an overview of the changing US epidemiology of cannabis use and associated problems. Adults and adolescents increasingly view cannabis as harmless, and some can use cannabis without harm. However, potential problems include harms from prenatal exposure and unintentional childhood exposure; decline in educational or occupational functioning after early adolescent use, and in adulthood, impaired driving and vehicle crashes; cannabis use disorders (CUD), cannabis withdrawal, and psychiatric comorbidity. Evidence suggests national increases in cannabis potency, prenatal and unintentional childhood exposure; and in adults, increased use, CUD, cannabis-related emergency room visits, and fatal vehicle crashes. Twenty-nine states have medical marijuana laws (MMLs) and of these, 8 have recreational marijuana laws (RMLs). Many studies indicate that MMLs or their specific provisions did not increase adolescent cannabis use. However, the more limited literature suggests that MMLs have led to increased cannabis potency, unintentional childhood exposures, adult cannabis use, and adult CUD. Ecological-level studies suggest that MMLs have led to substitution of cannabis for opioids, and also possibly for psychiatric medications. Much remains to be determined about cannabis trends and the role of MMLs and RMLs in these trends. The public, health professionals, and policy makers would benefit from education about the risks of cannabis use, the increases in such risks, and the role of marijuana laws in these increases.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Prevalence and Correlates of DSM-5 Cannabis Use Disorder, 2012-2013: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions–III

              Objective Attitudes towards marijuana are changing, the prevalence of DSM-IV cannabis use disorder has increased, and DSM-5 modified the diagnostic criteria for cannabis use disorders. Therefore, updated information is needed on the prevalence, demographic characteristics, psychiatric comorbidity, disability and treatment for DSM-5 cannabis use disorders in the US adult population. Method In 2012–2013, a nationally representative sample of 36,309 participants ≥18 years were interviewed in the National Epidemiologic Survey on Alcohol and Related Conditions-III (NESARC-III). Psychiatric and substance use disorders were assessed using the Alcohol Use Disorders and Associated Disabilities Interview Schedule-5. Results Prevalence of 12-month and lifetime marijuana use disorder was 2.5% and 6.3%. Among those with 12-month and lifetime marijuana use disorder, marijuana use was frequent; mean days used per year was 225.3 (SE=5.69) and 274.2 (SE=3.76). Odds of 12-month and lifetime marijuana use disorder were higher for men, Native Americans, those unmarried, with low incomes, and young adults, (e.g., OR=7.2, 95% CI 5.5–9.5 for 12-month disorder among those 18–24 years compared to those ≥45 years). Marijuana use disorder was associated with other substance disorders, affective, anxiety and personality disorders. Twelve-month marijuana use disorder was associated with disability. As disorder severity increased, virtually all associations became stronger. Only 24.3% with lifetime marijuana use disorder participated in 12-step programs or professional treatment. Conclusions DSM-5 marijuana use disorder is prevalent, associated with comorbidity and disability, and often untreated. Findings suggest the need to improve prevention methods, and educate the public, professionals and policy makers about the harms associated with marijuana use disorders and available interventions.
                Bookmark

                Author and article information

                Journal
                JAMA Netw Open
                JAMA Netw Open
                JAMA Netw Open
                JAMA Network Open
                American Medical Association
                2574-3805
                18 August 2020
                August 2020
                18 August 2020
                : 3
                : 8
                : e2013802
                Affiliations
                [1 ]Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York
                [2 ]New York State Psychiatric Institute, New York
                [3 ]Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York
                Author notes
                Article Information
                Accepted for Publication: June 2, 2020.
                Published: August 18, 2020. doi:10.1001/jamanetworkopen.2020.13802
                Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Gorfinkel LR et al. JAMA Network Open.
                Corresponding Author: Deborah Hasin, PhD, Columbia University Medical Center, 722 W 168th St, Room 228F, New York, New York 10032 ( dsh2@ 123456cumc.columbia.edu ).
                Author Contributions: Dr Hasin had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
                Concept and design: Gorfinkel, Hasin.
                Acquisition, analysis, or interpretation of data: All authors.
                Drafting of the manuscript: Gorfinkel.
                Critical revision of the manuscript for important intellectual content: All authors.
                Statistical analysis: Gorfinkel, Stohl.
                Administrative, technical, or material support: Gorfinkel, Hasin.
                Supervision: Hasin.
                Conflict of Interest Disclosures: None reported.
                Funding/Support: This study was supported by grant R01DA048860 from the National Institute on Drug Abuse to Dr Hasin and by the New York State Psychiatric Institute.
                Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
                Additional Contributions: We would like to thank Will Simmons, MPH, for his assistance with data cleaning and preparation and Claire Walsh, BSc, for her administrative support. Will Simmons was not compensated for his time; Claire Walsh was compensated for her time.
                Article
                zoi200521
                10.1001/jamanetworkopen.2020.13802
                7435337
                32809032
                cd9abbbf-90f4-40e6-9655-024ccd925780
                Copyright 2020 Gorfinkel LR et al. JAMA Network Open.

                This is an open access article distributed under the terms of the CC-BY License.

                History
                : 7 April 2020
                : 2 June 2020
                Funding
                Funded by: National Institute on Drug Abuse
                Categories
                Research
                Original Investigation
                Featured
                Online Only
                Substance Use and Addiction

                Comments

                Comment on this article